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Open aAbstract Background and aims: A recent genome-wide association study identified
rs2943641C > T, 500 kb from the insulin receptor substrate-1 gene (IRS1), as a type-2 diabetes
(T2D) susceptibility locus. We aimed to replicate this association by meta-analysis and examine
whether common variants within IRS1, present on the HumanCVD BeadChip, were associated
with T2D risk.
Methods and results: We genotyped rs2943641 in 2389 prevalent or incident T2D patients and
6494 controls from two prospective and three case studies based in UK and in the European
Atherosclerosis Research Study-II (EARSII; nZ 714). Thirty-three IRS1 variants had been geno-
typed in the prospective Whitehall-II study (n Z 4752) using the HumanCVD BeadChip. In
a fixed-effects meta-analysis of the UK study cohorts rs2943641T allele was associated with
6% lower risk of T2D (p Z 0.18), with T-allele carriers having an odds ratio (OR) of 0.89 (95%
confidence interval [CI]: 0.80e1.00, pZ 0.056) compared to CC subjects. The T-allele was alsosubstrate-1; T2D, Type-2 diabetes; CVD, Cardiovascular disease; GWAS, Genome-wide association
rphism; HOMA-IR, Homeostasis model assessment of insulin resistance; OGTT, Oral glucose tolerance
, Whitehall-II; NPHSII, Northwick Park Heart Study-II; UDACS, UniversityCollege London Diabetes and
abetes Study; PREDICT, PRospective Evaluation of Diabetic Ischemic heart disease by Computed
sclerosis Research Study-II; DIAGRAM, Diabetes Genetics Replication and Meta-analysis Consortium.
207 679 6968; fax: þ44 0 207 679 6212.
c.uk (S.E. Humphries).
e Supplementary material for full author list).
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IRS1 gene variants, dysglycaemic metabolic changes and type-2 diabetes risk 1025associated with lower fasting insulin and homeostasis model assessment index of insulin resis-
tance in Whitehall-II and with lower post-load insulin after an oral glucose tolerance test in
EARSII (all p < 0.05). None of the IRS1 variants on the chip showed linkage disequilibrium with
rs2943641. In silico analysis with follow-up genotyping (total nZ 9313) identified that the rare
allele of the IRS1 promoter variant rs6725556A > G showed association with reduced T2D risk
(OR per G-allele: 0.82, 95%CI: 0.69e0.96, p Z 0.015).
Conclusions: We confirm the association of rs2943641T with T2D protection. There is a possible
independent effect on risk of a putative IRS1 promoter variant.
ª 2011 Elsevier B.V. Open access under CC BY license.Introduction
Genome-wide association studies (GWAS) have identified
multiple loci at which common variants modestly but repro-
ducibly influence risk of type-2 diabetes (T2D) [1e6].
Currently, single nucleotide polymorphisms (SNPs) in w40
genetic loci have been associated with T2D [7,8], most of
whichrelateto insulinsecretionratherthan insulin resistance
[8,9], have been distinct from previously studied candidate
genes[10],anddonotseemtooffergreaterpredictivevaluein
determiningdiabetes risk thandocommonlyusedphenotypic
risk factors and family history [11,12].
Rung and colleagues [13] identified rs2943641C > T,
located 500 kb downstream of the insulin receptor
substrate-1 gene (IRS1), as a T2D risk locus, with the major
C-allele being associated with 19% increased risk of T2D.
Importantly, unlike other reported T2D loci, the rs2943641C
allele was associated with increased fasting- and glucose-
stimulated hyperinsulinemia and impaired insulin sensi-
tivity. Lower IRS1-associated phosphatidylinositol-3eOH
kinase activity in human skeletal muscle biopsies was also
shown for the C-allele during insulin infusion, and in vitro
studies showed that this allele was associated with lower
IRS1 protein expression in the basal state, suggesting
a direct regulatory link between rs2943641 and IRS1 [13].
The Diabetes Genetics Replication and Meta-analysis
Consortium (DIAGRAM) in an earlier meta-analysis did not
identify this SNP as a T2D risk variant [4]; however, in
a subsequent publication [6] a different IRS1 SNP
(rs7578326) adjacent to and in strong linkage disequilibrium
(LD) with rs2943641 (r2 Z 0.79, in HapMap CEU) was re-
ported to be associated with T2D.
The purpose of this study was to validate the rs2943641
association with T2D risk and diabetes-related quantitative
traits using data from UK population-based cohorts and T2D
patients. In addition, using data from 4752 Caucasians
participating in the Whitehall-II study who had been geno-
typed for 33 IRS1 SNPs using the HumanCVD BeadChip
[14,15] and with follow-up direct genotyping of IRS1 SNPs in
the other study cohorts, we explored the potential associ-
ation with the risk of T2D of SNPs within and flanking IRS1.
Methods
Study cohorts
Full details of the 6 studies, Whitehall-II (WHII), Northwick
Park Heart Study-II (NPHSII), University College LondonDiabetes and Cardiovascular Study (UDACS), Ealing Diabetes
Study (EDS), PRospective Evaluation of Diabetic Ischemic
heart disease by Computed Tomography (PREDICT) and
European Atherosclerosis Research Study-II (EARSII) are
presented in the Supplementary Methods section and in
Supplemental Table 1. All studies were approved by their
institutional ethics committees and all subjects gave
written informed consent.
Insulin resistance and HbA1c determination
In EARSII and WHII insulin resistance estimates were derived
using the homeostasis model assessment index of insulin
resistance (HOMA-IR) Z fasting insulin (pmol/l)  fasting
glucose (mmol/l)/156.3 [16]. Insulin sensitivity and b-cell
function were also accessed using the oral glucose toler-
ance test (OGTT) [17]. HbA1c was measured in EDTA-whole
blood on a calibrated high-performance liquid chromatog-
raphy system with automated haemolysis before injection
[18].
Genotyping
In silico data for SNPs spanning IRS1 was obtained from WHII
where genotyping had been undertaken using the 50K-
HumanCVD BeadChip (Illumina, San Diego, USA) [14,15].
Thirty-three SNPs present on the chip, located either in
coding, non-coding, or in the flanking region of IRS1 (within
5 kb upstreamor downstream of the gene), were considered.
Ten SNPs were monomorphic in WHII, while for the rest,
minor allele frequencies among T2D-free individuals were in
the range of 0.023e0.111 (Supplementary Table 2). Direct
genotyping of rs2943641 in all cohorts and of IRS1 rs6725556
in other study cohorts was carried out using TaqMan on the
ABI-7900HT platform (Applied Biosciences, Warrington, UK).
Random duplicates were used as quality control with call
rates >96%. In all studies, genotype distribution was as ex-
pected from Hardy-Weinberg proportions.
Statistical analysis
For continuous variables results are presented asmean SD.
Non-normally distributed variables were logarithmic or
square-root transformed and means were transformed back
and SDs are approximate for these variables. In WHII,
glucose, insulin, HOMA-IR, HbA1c, systolic-blood pressure
(BP), diastolic-BP and body mass index (BMI) were log-
transformed. In EARSII, insulin values were square-root
transformed and cholesterol, BMI, and systolic-BP were
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Figure 1 Plasma insulin concentration after an OGTT by
rs2943641 genotype in European Atherosclerosis Research
Study-II. Data are presented as mean  SEM in carriers of the
CC (white circles), CT (white squares) and TT (black triangles)
genotypes. )p Z 0.004, ))p Z 0.03, )))p Z 0.09, for
additive model adjusting for age, “case”/“control” status and
region. P-values for AUC insulin: p Z 0.005 (additive),
p Z 0.003 (dominant), confirming result reported by Rung
et al. [13].
1026 N. Yiannakouris et al.log-transformed. P-values are adjusted for covariates using
analysis of covariance models. Categorical variables are
presented as percentage and number, and are compared
using chi-squared tests. Glucose, insulin and HOMA-IR were
compared using data from all phases in WHII (phases 3, 5 and
7) using multi-level mixed regression (random-intercept
model). Adjustment was made for age, BMI and gender, and
dummyvariableswerefitted for phase-5 andphase-7 in order
to take account of differences in measurements over time.
Diabetes status, as the outcome, was analysed by logistic
regression with adjustment for age and where applicable for
gender and recruitment centre. Results for rs2943641 and
rs6725556were combined over all cohorts using fixed-effects
meta-analysis. In WHII a set of non-redundant IRS1 SNPs
independently associated with T2D was determined by vari-
able selection, using stepwise regression based on the
Bayesian information criterion [19]. An additive genetic
model was assumed. Of the 23 SNPs, 18 with p < 0.25 on
univariate analysis were initially selected for possible
inclusion in themultivariate model. Statistically significance
was taken as p < 0.01. Following the suggestion of Rothman
[20], this more conservative p-value was used in preference
to correcting for multiple comparisons.
Results
Association of rs2943641 with diabetes-related
quantitative traits
Baseline clinical, biochemical, and the genetic characteris-
tics of the subjects in WHII and NPHSII are presented in
SupplementaryTable3. Subjectswhowenton todevelopT2D
were more likely to be obese and hypertensive, and in WHII
had, as expected, higher baseline fasting glucose and insulin
levels, higher percentage of HbA1c and a higher HOMA-IR
index (all p < 0.001). There were no significant genotype
differences between T2D cases and controls; however, in
WHII the rs2943641T allele was associated with lower fasting
insulin (p Z 0.04) and HOMA-IR (p Z 0.03) in a mixed
regression model over all study phases while adjusting for
age, gender, BMI and study phase (Supplementary Table 4).
The overall characteristics of the T2D patients in UDACS,
EDS and PREDICT by ethnic group and rs2943641 genotype,
are presented in Supplementary Tables 5 and 6. In compar-
ison to European whites, patients of Indian Asian origin had
an earlier age of onset of the disease, a lower prevalence of
obesity and were less frequently smokers and carriers of the
rs2943641Tallele (Supplementary Table 5). No differences in
any baseline biochemical measures, including fasting
glucose and HbA1c, were observed across genotypes in the
two ethnic groups (Supplementary Table 6).
In EARSII, there was no ‘case’/‘control’ heterogeneity in
age, BMI, BP, fasting glucose or rs2943641 genotype distri-
bution (Supplementary Table 3) and therefore, ‘cases’ and
‘controls’ were combined in subsequent analyses. No
significant differences across genotypes for any of the
fasting biochemical variables were observed in this cohort
of young individuals; however, rs2943641T allele was asso-
ciated with lower insulin levels after OGTT (Fig. 1). The
effect of rs2943641T appeared to be dominant, with
T-allele carriers having area under the curve (AUC) forinsulin 13.3% lower than CC homozygotes (p Z 0.003). The
difference among genotypes was significant at 60 and at
90 min after the OGTT (p Z 0.004 and p Z 0.03, respec-
tively, Fig. 1). There was no evidence for heterogeneity
between ‘cases’ and ‘controls’ for AUCinsulin (pZ 0.47), nor
were any differences between genotype groups for
AUCglucose (Supplementary Table 7). OGTT-derived indexes
of insulin sensitivity as reflected by metabolic clearance
rate (MCR) and the insulin sensitivity index (ISI), and b-cell
function as reflected by 1st and 2nd phase insulin release
[17], showed that both MCR and ISI were significantly
associated with rs2943641 genotype (Table 1).
Impact of rs2943641 on T2D risk
The association of rs2943641 with T2D in the study pop-
ulations was examined using logistic regression with
adjustment for age plus gender and general practice
recruitment where applicable. For European white T2D
patients, the NPHSII T2D-free group was used for compar-
ison (n Z 2489), whereas for Indian Asians the WHII Asian
non-diabetic participants (nZ 146) were used. Fig. 2 shows
odds ratios (ORs) and 95% confidence intervals (CI) for T2D
for each additional T-allele carried (additive effect).
Overall, the rs2943641T allele was associated with a 6%
decreased risk of T2D (p Z 0.18 for an additive model),
with T-allele carriers having a OR of 0.89 (95%CI:
0.80e1.00, p Z 0.056) compared to CC subjects.
Association of IRS1 SNPs with T2D risk in WHII
The association of the IRS1 SNPs on the HumanCVD Bead-
Chip (used to genotype in WHII) with T2D risk are presented
in Supplementary Tables 2 and 4. None of these SNPs were
Table 1 OGTT-derived indexes of insulin sensitivity, metabolic clearance rates, and first and second phase insulin release
based on Strumvoll et al [17]in EARSII.
rs2943641
genotype
Insulin
sensitivity index
p-valuea Metabolic
clearance rate
p-valuea First phase
insulin release
p-valuea Second phase
insulin release
p-valuea
CC 0.118 (0.001) 9.96 (0.072) 1225.2 (24.3) 324.3 (5.3)
CT 0.121 (0.001) 0.008 10.21 (0.071) 0.008 1197.8 (23.4) 0.83 317.7 (10.4) 0.72
TT 0.122 (0.002) 10.29 (0.139) 1235.7 (47.3) 325.0 (10.4)
Abbreviations: OGTT Z oral glucose tolerance test; EARSII Z European Atherosclerosis Research Study-II.
Results are mean  SEM.
a P-values adjusted for age, ‘case’/‘control’ status and region.
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the CEU population, or in WHII, although strong LD
(r2 > 0.6) between several IRS1 SNPs was observed in WHII
(Supplementary Fig. 1). Eight IRS1 SNPs showed suggestive
evidence for an association of the minor alleles with
a decreased risk of T2D (p-values 0.05), but no association
with diabetes-related quantitative traits, including fasting
and 2-h after OGTT glucose and insulin concentrations,
were observed (Supplementary Table 4). Seven of these
SNPs represent two LD-blocks within IRS1 (Supplementary
Figure 1), while rs6725556 is located 3538 nucleotides
upstream of the IRS1 translation start site.
Using a variable selection model including all risk-
associated IRS1 variants, age, gender and BMI considered
for entry, we identified that rs6725556 (OR per minor
G-allele: 0.50, 95%CI: 0.33e0.78, p Z 0.002) and SNP
rs2943641 near IRS1 (OR per minor T-allele: 0.82, 95%CI:
0.69e0.99, p Z 0.04) were the only variants that were
independently associated with T2D risk in WHII, along with
age (p < 0.001) and BMI (p < 0.001). The two SNPs appearedOverall
NPHSII
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Figure 2 Odds ratio (OR) and 95% confidence interval (CI) for
T2D per rs2943641T allele (additive genetic model) in the
various populations of this study. Heterogeneity chi-
squaredZ 0.73 (d.f.Z 3), pZ 0.87; I-squared (variation in OR
attributable to heterogeneity) Z 0.0%. ORs were adjusted for
age and where applicable for gender and centre. Abbrevia-
tions: NPHSII Z Northwick Park Heart Study-II;
WHII Z Whitehall-II; EW Z European Whites (UDACS, EDSC
and PREDICT combined); IA Z Indian Asians (UDACS, EDSC and
PREDICT combined).to have an additive effect (logistic scale) on risk with no
statistically significant evidence for interaction
(pinteraction Z 0.15). Considering subjects homozygous for
rs2943641C as the reference category, the risk of being an
incident T2D case was lower in carriers of both minor alleles
of the rs2943641 and rs6725556 polymorphisms (OR: 0.48,
95%CI: 0.27e0.84, p Z 0.01) compared to carriers of the
rs2943641T allele alone (OR: 0.70, 95%CI: 0.54e0.90,
pZ 0.006).
Impact of IRS1 rs6725556 on T2D risk
To assess further the impact of rs6725556A > G on T2D risk
we genotyped this SNP in NPHSII and in the T2D patients
(Supplementary Table 8). Compared to European white T2D
patients, the frequency of the variant rs6725556G allele
was twice as high in T2D patients of Indian Asian origin (0.06
vs. 0.12, respectively, p < 0.001). In all UK study cohorts,
there was a trend for an association of the G-allele with
decreased risk for T2D. Meta-analysis of individual partici-
pant data from all UK cohorts (Fig. 3) revealed that the
rs6725556G allele was associated with lower risk of T2D (OR
per G-allele: 0.82, 95%CI: 0.69e0.96; p Z 0.015).Discussion
We genotyped rs2943641C > T, located 500 kb downstream
of IRS1, in 2389 prevalent or incident T2D patients and 6494
controls from two prospective and three case studies based
in UK and found evidence for an association of the minor
rs2943641T allele with T2D protection. This allele was
associated with lower fasting insulin and HOMA-IR index in
middle-aged participants of the WHII study and with lower
post-load insulin after OGTT in young adults of the EARSII
study. In silico analysis with follow-up genotyping also
identified that the minor allele of the IRS1 promoter variant
rs6725556A > G showed association with reduced T2D risk
(OR per G-allele: 0.82, 95%CI: 0.69e0.96, p Z 0.015).
Rung and colleagues [13] identified rs2943641 as a T2D
susceptibility locus in a multistage association study across
14,051 French and Danish individuals (6258 cases and 7793
controls) and showed strong association of the major
C-allele with increased risk of T2D (OR: 1.19, 95%CI:
1.13e1.25, pZ 9.3  1012). This result is equivalent to OR
per T-allele: 0.84, 95%CI: 0.80e0.88. Our findings in these
UK studies are consistent with an association of rs2943641T
with 6% decreased risk of T2D (OR per T-allele: 0.94, 95%CI:
Overall
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0.82 (0.69, 0.96)
0.80 (0.50, 1.30)
0.62 (0.42, 0.90)
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Figure 3 Odds ratio (OR) and 95% confidence interval (CI) for
T2D per IRS1 rs6725556G allele (additive genetic model) in the
various populations of this study. Heterogeneity chi-
squared Z 4.36 (d.f. Z 3), p Z 0.23; I-squared Z 31.1%. ORs
were adjusted for age and where applicable for gender and
centre. Abbreviations: NPHSII Z Northwick Park Heart Study-
II; WHII Z Whitehall-II study; EW Z European Whites;
IA Z Indian Asians.
1028 N. Yiannakouris et al.0.87e1.03, pZ 0.18). This association became statistically
significant when analyses were repeated with additional
adjustment for BMI (overall OR: 0.88; 95%CI: 0.80e0.96,
pZ 0.006), although since there was no relationship of this
SNP with BMI, and GWAS of genetic variants influencing BMI,
obesity and related phenotypes have not identified IRS1 as
a BMI related gene [8], the mechanism of this is unclear.
Notably, data from the recently published DIAGRAM
meta-analysis [6] identified a different SNP
(rs7578326A > G) adjacent to rs2943641 to be associated
with T2D (OR per A-allele: 1.11, 95%CI: 1.08e1.13,
p Z 5.4  1020; 42,542 cases and 98,912 controls). The
two SNPs liew73 kb apart and are in strong LD (r2Z 0.79 in
HapMap CEU), and therefore this finding provides further
confirmation of the previously reported signal. Moreover,
using data from up to 46,186 non-diabetic subjects from the
Meta-Analyses of Glucose and Insulin-related traits
Consortium the authors reported the risk allele to be
associated with higher fasting insulin [6], consistent with
a primary effect on insulin action.
Rung and colleagues [13] also examined the effect of
rs2943641 on diabetes-related quantitative traits in three
independent cohorts with normoglycemic individuals of
Finnish, French and Danish origin (n Z 14,358) and found
that the diabetogenic rs2943641C allele was associated
with higher fasting insulin and HOMA-IR indices, but not
with fasting glucose levels. In middle-aged Danes, the
C-allele was also associated with higher insulin levels after
OGTT [13]. Concordant with those findings, we found an
association of the minor rs2943641T allele with lower
fasting insulin (p Z 0.04) and HOMA-IR (p Z 0.03) in
middle-aged individuals of WHII study, and no association
with fasting glucose levels. We have also taken this study
forward by examining the association of this variant with
insulin levels after an OGTT. The T-allele was associatedwith lower post-load insulin levels in the healthy young
males of EARSII (13.3% lower AUCinsulin, p Z 0.003), but it
was not associated with fasting insulin or HOMA-IR, which
implies that a significant association of rs2943641T with
lower fasting insulin levels may be evident or become
established only later in life.
The importance of IRS1 in insulin signaling has been
confirmed in studies showing that this gene is associated
with peripheral insulin sensitivity as well as in the
regulation of insulin secretion [21,22] and a functional
IRS1 variant (Gly972Arg, rs1801278) has been related to
T2D risk [23], although some studies have failed to
replicate this [24,25]. Rs1801278 was present on the 50K-
chip [14] and in WHII it did not show significant associ-
ation with T2D risk (OR: 1.20, 95%CI: 0.88e1.63,
p Z 0.25). Morini and colleagues [26] in their meta-
analysis of 32 studies suggest that when analysis took
into account age of onset of disease (data from 14
studies) there was evidence that this variant was more
strongly associated with risk in the tertile of those who
had early-onset disease. Our results support this
(Supplementary Table 9) but our study was not powered
to find a significant interaction (p Z 0.15).
In our exploration of T2D risk as a function of 23 poly-
morphic IRS1 variants on the HumanCVD BeadChip using
data from WHII [12,15], with follow-up genotyping in other
study cohorts, we found evidence for a possible indepen-
dent effect on risk of a genetic variant in the 50-flanking
region of IRS1 (rs6725556; 3538A > G), although no test
met our prespecified criteria of p < 0.01 for statistical
significance. Specifically, the G-allele of rs6725556 was
associated with 18% lower risk of T2D in a meta-analysis of
individual participant data from all UK-study cohorts
(p Z 0.015). This variant, together with rs2943641 near
IRS1, was independently associated with T2D risk in WHII
using a variable selection model with adjustment for age,
gender and BMI (OR: 0.50, 95%CI: 0.33e0.78, pZ 0.002 and
OR: 0.82, 95%CI: 0.69e0.99, p Z 0.04, respectively) and
appeared to have an additive effect on risk. No corrections
have been made for multiple comparisons and so these
effects should be interpreted cautiously. Rs6725556 and
rs2943641 lie 573.5 kb apart, and show no LD (r2 Z 0.0 in
WHII) and although they were both associated with risk of
T2D, rs6725556 was not associated with fasting and post-
load insulin levels and HOMA-IR. Interestingly, transcrip-
tion factor binding site analysis using the MatInspector
software tool (http://www.genomatix.de/products/
MatInspector/) revealed that rs6725556G abolishes a PAX-
2/5/8 binding site. The paired-box (PAX) gene family
encodes a group of transcription factors that have emerged
as important regulators of organogenesis in all species [27]
and PAX2 has been shown to be expressed in endocrine
pancreas where one of its functions may be the regulation
of pancreatic hormone genes [28]. This could be of rele-
vance in the pathogenesis of diabetes and other endocrine
disorders; however, whether rs6725556 is indeed a func-
tional polymorphism affecting IRS1 expression needs to be
proven in future functional studies. Moreover, we
acknowledge that these results are preliminary and that
replication of our findings in independent cohorts is
essential. We also acknowledge that a limitation of our
study is that it is underpowered to detect an association in
IRS1 gene variants, dysglycaemic metabolic changes and type-2 diabetes risk 1029the Indian Asian cohort. We only have 24% power to detect
the association found by Rung and colleagues [13]
(OR Z 0.84) for rs2943641. However, for the Whites we
have 99% power to detect a OR of 0.84. If we take account
of multiple comparisons for the 6 traits (Supplementary
Table 4) we would still have 94% power.
In summary, this report confirms the association of the
major C-allele of rs2943641 near IRS1 with increased risk of
T2D, fasting- and glucose-stimulated hyperinsulinemia and
impaired insulin sensitivity. Our data also suggest that
rs2943641 and an IRS1 putative promoter variant (rs6725556)
may independently influence T2D risk, although further
studies with larger cohorts are needed to confirm the etio-
logical SNPs and to analyze their interactions in different
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